Rationale and Objectives
To evaluate single-institution outcomes of drug-eluting bead transarterial chemoembolization
(DEB-TACE) in the treatment of locally advanced neuroendocrine tumor (NET) hepatic
metastases with a focus on safety and efficacy of treatment.
Materials and Methods
A single-center retrospective cohort study of the outcomes of consecutive patients
with NELM who underwent DEB-TACE between 2014 and 2019 was performed. Clinicopathologic
characteristics, radiologic response (modified Response Evaluation Criteria in Solid
Tumors) at 1-month follow-up, adverse events, progression-free survival (PFS), and
overall survival were calculated.
Results
Among 287 patients (mean age of 62 years; 39% male: 61% female), disease burden was
bilobar (90.2%) with mean largest tumor diameter measuring 4.9 ± 2.8 cm. Of these
patients, 14.6% had no evidence of tumor in other organs or lymph nodes. Complete
response occurred in 60 (20.9%) patients while 133 (46.3%) had partial responses.
Major complication occurred in 2.4%. Liver function tests including total bilirubin
and AST were overall stable at the 1-month follow-up, with only a small increase in
the ALT at +8.9% (p < 0.01). Overall survival was 80.1% at 1 year, 49.1% at 3 years, and 12.3% at 5 years
with a mean PFS of 14.4 ± 12.5 months.
Conclusion
Based on this institutional experience, DEB-TACE is an acceptable locoregional therapy
choice for hepatic metastases of NET due to its tolerable safety profile and relative
efficacy.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Academic RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The classification of carcinoid tumours.Lancet Oncol. 1963; 1: 238-239https://doi.org/10.1016/s0140-6736(63)90951-6
- Gastroenteropancreatic high-grade neuroendocrine carcinoma.Cancer. 2014; 120: 2814-2823https://doi.org/10.1002/cncr.28721
- Recommendations for management of patients with neuroendocrine liver metastases.Lancet Oncol. 2014; 15: e8-e21https://doi.org/10.1016/S1470-2045(13)70362-0
- Metastatic disease to the liver: locoregional therapy strategies and outcomes.World J Clin Oncol. 2021; 12: 725-745https://doi.org/10.5306/wjco.v12.i9.725
- Current status of interventional radiology in the management of gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs).Cardiovasc Intervent Radiol. 2015; 38: 13-24https://doi.org/10.1007/s00270-014-1005-z
- Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis.Curr Oncol. 2020; 27: e537-e546https://doi.org/10.3747/co.27.6205
- Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma.World J Hepatol. 2017; 9: 808-814https://doi.org/10.4254/wjh.v9.i18.808
- Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET): first safety report.J Vasc Interv Radiol. 2019; 30: S49-S50https://doi.org/10.1016/j.jvir.2018.12.151
- Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.Semin Liver Dis. 2010; 30: 52-60https://doi.org/10.1055/s-0030-1247132
- Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of Practice Committee [published correction appears in J Vasc Interv Radiol. 2018 Jan;29(1):146].J Vasc Interv Radiol. 2017; 28: 1432-1437.e3https://doi.org/10.1016/j.jvir.2017.06.019
- Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020; 9: 440-451https://doi.org/10.21037/hbsn.2020.04.02
- Conventional versus drug-eluting bead transarterial chemoembolization for neuroendocrine tumor liver metastases.J Vasc Interv Radiol. 2016; 27: 1298-1304https://doi.org/10.1016/j.jvir.2016.05.014
- Liver transarterial embolizations in metastatic neuroendocrine tumors.Rev Endocr Metab Disord. 2017; 18: 459-471https://doi.org/10.1007/s11154-017-9431-2
- Transarterial (chemo)embolization for liver metastases in patients with neuroendocrine tumors.Oncology. 2017; 92 (Epub 2017 Mar 23): 353-359https://doi.org/10.1159/000463388
- Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.Gastroenterology. 2010; 138: 52-64https://doi.org/10.1053/j.gastro.2009.09.006
- Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis.J Am Coll Surg. 2020; 230 (Epub 2020 Feb 4): 363-370https://doi.org/10.1016/j.jamcollsurg.2019.12.026
Article info
Publication history
Published online: April 25, 2023
Accepted:
March 29,
2023
Received in revised form:
March 26,
2023
Received:
January 22,
2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved All rights reserved.
